CCL2 and atherosclerosis: In our research, EPA lowered monocyte chemotactic protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL-2) levels in serum, which means that EPA could attenuate inflammatory responses during atherosclerosis (Figure 1(f)).